

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2023

FOR

ALPHA BIOLABORATORIES COVID-19 TESTING  
LIMITED

**ALPHA BIOLABORATORIES COVID-19 TESTING  
LIMITED (REGISTERED NUMBER: 12845735)**

**CONTENTS OF THE FINANCIAL STATEMENTS**  
for the Year Ended 31st March 2023

---

	<b>Page</b>
<b>Company Information</b>	<b>1</b>
<b>Balance Sheet</b>	<b>2</b>
<b>Notes to the Financial Statements</b>	<b>3</b>

---

**ALPHA BIOLABORATORIES COVID-19 TESTING  
LIMITED**

**COMPANY INFORMATION**

for the Year Ended 31st March 2023

---

**DIRECTORS:**

Mr D Thomas  
Ms R Thomas

**REGISTERED OFFICE:**

14 Webster Court  
Carina Park  
Westbrook  
Warrington  
WA5 8WD

**REGISTERED NUMBER:**

12845735 (England and Wales)

**ALPHA BIOLABORATORIES COVID-19 TESTING  
LIMITED (REGISTERED NUMBER: 12845735)**

**BALANCE SHEET**

**31st March 2023**

		<b>2023</b>	<b>2022</b>
	Notes	£	£
<b>CURRENT ASSETS</b>			
Debtors	4	<b>881,121</b>	869,616
<b>CREDITORS</b>			
Amounts falling due within one year	5	<b><u>(182,139)</u></b>	<u>(170,134)</u>
<b>NET CURRENT ASSETS</b>		<b><u>698,982</u></b>	<u>699,482</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b><u>698,982</u></b>	<u>699,482</u>
<b>CAPITAL AND RESERVES</b>			
Called up share capital	6	<b>100</b>	100
Retained earnings		<b><u>698,882</u></b>	<u>699,382</u>
<b>SHAREHOLDERS' FUNDS</b>		<b><u>698,982</u></b>	<u>699,482</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st March 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st March 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 27th December 2023 and were signed on its behalf by:

Mr D Thomas - Director

The notes form part of these financial statements

**ALPHA BIOLABORATORIES COVID-19 TESTING  
LIMITED (REGISTERED NUMBER: 12845735)**

**NOTES TO THE FINANCIAL STATEMENTS**  
for the Year Ended 31st March 2023

---

**1. STATUTORY INFORMATION**

Alpha Biolaboratories Covid-19 Testing Limited is a private company, limited by share capital, incorporated in England and Wales, registration number 12845735. The address of the registered office and principal place of business is Unit 14 Webster Court, Carina Park, Westbrook, Warrington WA5 8WD.

**2. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Turnover**

Turnover represents amounts recognised by the company in respect of goods supplied, exclusive of Value Added Tax and trade discounts. Turnover principally consists of the sale of COVID-19 testing kits and processing of the test results which are recognised at the point of which the goods or services are provided.

**Trade and other debtors**

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method, less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases, the trade debtors and other debtors are stated at cost less impairment losses for bad and doubtful debts.

**Trade and other creditors**

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method unless the effect of discounting would be immaterial, in which case they are stated at cost.

**Cash and cash equivalents**

Cash and cash equivalents are represented by cash in hand and at bank.

**3. EMPLOYEES AND DIRECTORS**

The average number of employees during the year was NIL (2022 - NIL).

**4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2023	2022
	£	£
Trade debtors	-	128,857
Other debtors	<u>881,121</u>	<u>740,759</u>
	<u>881,121</u>	<u>869,616</u>

**5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2023	2022
	£	£
Other creditors	<u>182,139</u>	<u>170,134</u>

**ALPHA BIOLABORATORIES COVID-19 TESTING  
LIMITED (REGISTERED NUMBER: 12845735)**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
for the Year Ended 31st March 2023

---

**6. CALLED UP SHARE CAPITAL**

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	<b>2023</b>	2022
			<b>£</b>	£
100	Ordinary	£1.00	<b><u>100</u></b>	<u>100</u>

**7. RELATED PARTY DISCLOSURES**

During the year, the company paid laboratory fees to companies under common control of £Nil (2022: £3,601,521).

At the balance sheet date the business owed £181,040 (2022: £169,534) to companies under common control.

At the balance sheet date the business was owed £118,746 (2022: £3) from companies under common control.

**8. ULTIMATE CONTROLLING PARTY**

The ultimate controlling party are the directors of the business by virtue of their controlling interest in the business.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.